3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
4
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
13
Gastrointestinal
9
Breast
9
Other hematologic neoplasm
7
Thoracic
6
Plasma cell
6
Lymphoid
5
Tumor-Agnostic
4
Head & Neck
4
Gynecologic
4
CNS
4
Dermatologic
2
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Interventions
Azacitidine
68
nilotinib
50
Imatinib Mesylate
50
ruxolitinib
42
Dasatinib
25
venetoclax
22
Decitabine
20
bosutinib
18
asciminib
17
Cytarabine
15
ponatinib
10
decitabine and cedazuridine drug combination
10
AP 1903 reagent
10
Cyclophosphamide
9
fludarabine
8
Hydroxyurea
8
navitoclax
6
ON 01910
6
sabatolimab
5
pevonedistat
5
mocetinostat
5
luspatercept
5
itacitinib
5
imetelstat
5
givinostat hydrochloride
5
givinostat
5
fludarabine phosphate
5
avapritinib
5
Mycophenolic Acid
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Standard of Care
×
Myeloid
×
Clear all
NCT05316701
2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3
Active not recruiting
187 enrolled
15 charts